Sales & Marketing News | pharmaphorum

News

Teva fined €462.6m for antitrust delay to MS drug rivals

The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copax

News

AZ confirms its China president is under investigation

The head of AstraZeneca's Chinese operations has been placed under investigation by the authorities in Beijing, although the reasons for the probe remain unclear.

News

Novartis gets FDA okay for frontline use of Scemblix in CML

Novartis has picked up a new FDA approval for its chronic myeloid leukaemia therapy Scemblix that it believes is critical to unlocking the drug's blockbuster sales potential.

News

Alarm bell rings for GSK as US policy dents RSV jab sales

Sales of GSK's respiratory syncytial virus (RSV) vaccine Arexvy slumped 72% in the third quarter of this year, as narrower recommendations on its use in the US started to have an effect.

News

Pfizer rebuffs Starboard criticism as it raises forecasts

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist investor for complaining about the company's direction without c

News

Joy as NICE lifts restrictions on myeloma drug Elrexfio

Patients in England and Wales with multiple myeloma are celebrating a decision by NICE to relax strict restrictions on eligibility to receive Pfizer's Elrexfio.

Teva fined €462.6m for antitrust delay to MS drug rivals

AZ confirms its China president is under investigation

Novartis gets FDA okay for frontline use of Scemblix in CML

Alarm bell rings for GSK as US policy dents RSV jab sales

Pfizer rebuffs Starboard criticism as it raises forecasts

Joy as NICE lifts restrictions on myeloma drug Elrexfio

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks